Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Articles

T-cell response to unique and shared antigens and vaccination of cancer patients

Giorgio Parmiani, Marialuisa Sensi, Chiara Castelli, Licia Rivoltini and Andrea Anichini
Giorgio Parmiani
1Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marialuisa Sensi
2Unit of Immunobiology of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chiara Castelli
1Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Licia Rivoltini
1Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Anichini
2Unit of Immunobiology of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Most vaccination studies of cancer patients find no clear association between clinical and immunological responses to the vaccine. We discuss the possible kinetics of the T cell response in melanoma patients against unique or shared tumor antigens. We hypothesize that a response against unique antigens prevails during primary melanoma growth, causing the selection of tumor cells lacking most of these antigens unless these are necessary to maintain the neoplastic state. After a subset of tumor cells metastasize to the lymph nodes, T cells are activated against previously ignored shared, differentiation-like antigens, owing to a new environment where pro-inflammatory cytokines can be present. The development of a T cell response to such normal epitopes then associates with tumor growth, but remains clinically inefficient. We predict that two immunologically different subsets of melanoma patients may exist, one that mounted an early immune response against melanoma antigens and one that did not. A paradox may emerge when vaccination is attempted in these two groups of subjects, with the second group being more prone to develop an effective immune response if the vaccine is potent enough to activate naive T cells, while the first has probably already eliminated most of the tumor antigens potentially recognizable by the host T cells owing to the previous selection made by the immune response developed early during tumor growth. Thus, it is likely that the subgroup of metastatic patients with a high frequency of anti-melanoma memory T cells may not show a clinical response to vaccination.

This article was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

Introduction

During the last few years the results of clinical studies of vaccination with class I HLA-restricted tumor peptides recognized by T cells have been published, not only for metastatic melanoma patients (1, 2, 3, 4, 5, 6, 7) but also for other types of cancer (e.g. pancreatic or prostate) (8, 9). A paradox is apparent in the majority of these reports, namely that the vaccine-specific response of the patients' peripheral blood cytotoxic T lymphocytes was not associated with the clinical outcome, but rather that the occurrence of clinical responses tended to exclude anti-vaccine immune reactions and vice versa (1, 3, 4, 10, 11, 12, 13, 14). Even the use of dendritic cell-based vaccines fails to alter the overall picture. In fact, while DC-based immunization clearly increases the strength and frequency of anti-vaccine T-cell responses, no significant improvements were observed in the clinical response rate of patients having undergone DC-based vaccination as compared to that obtained in vaccination trials not involving DCs (2, 5, 15).

What we would like to propose is that such a lack of association between tumor-specific, alphabeta T lymphocyte-mediated responses to vaccine antigens and clinical outcome reflects the immune status of patients, as determined by their previous exposure to the cancer antigens subsequently used for vaccination. To explain our hypothesis, we will try to recapitulate the possible kinetics of interaction between alphabetaT cells and cancer antigens using human melanoma as paradigm.

Tumor-host relationship during primary tumor growth

During primary melanoma growth, cutaneous lesions may present with infiltration of T lymphocytes most likely due to recognition of tumor antigens by T cells (16, 17) and often accompanied by an area of tumor regression. In fact, albeit in rare occasions (owing to the difficulty of isolating such cells), T lymphocytes deriving from primary lesions, including regressing ones, could be shown to destroy autologous melanoma cells in vitro and to encompass dominant clonotypes (18, 19). Moreover, spontaneous regression was associated with the presence of an infiltrate expressing a TH1 cytokine profile, as evaluated by PCR and in situ hybridization (20).

This suggests that a local, and perhaps systemic, sensitization against one or more melanoma antigens can occur during primary melanoma growth. This early antigen recognition by T cells could lead to either (i) an elimination of the most aggressive, metastasis competent, melanoma cells, which would explain the better prognosis of primary lesions characterized by brisk lymphocyte infiltration (21), or (ii) a selection in favor of tumor cells expressing antigen(s) not recognized by the infiltrating lymphocytes, or not expressing antigens at all, and thus endowed with an immunologically unrestricted metastatic potential (Figure 1). In fact, partial regression of primary melanoma is considered a bad prognostic factor at least by some authors (16). A side-effect of such a first selection could also be the elimination of tumor cells which express high levels of the given class I HLA allele, thus reducing the possibility that other peptide/HLA complexes could be seen by the host's T cells. In fact, the downregulation or absence of class I HLA has been reported even for primary melanoma lesions, although only in 10-16% of cases (22). The concept that the immune response can not only protect against the development of carcinogen-induced and spontaneous immunogenic tumors, but also select neoplastic cells with reduced immunogenicity, has been recently proven using wild-type and immunodeficient mice with targeted disruptions of either the recombination activating gene 2 (RAG2) or the gene encoding the transcription factor mediating signaling by the interferon-gamma and interferon alpha/beta receptors (23). It is of note that, in addition to alphabeta T lymphocytes, even gammadelta T and NK cells may participate in immune surveillance against tumors (24) although, in the case of human melanoma, such a process is likely to occur early in the process of UV carcinogenesis. In this phase of the innate type of antitumor reaction, NK and/or gammadelta T lymphocytes can recognize MIC/A/B or HLA-G antigens on tumor targets by the NKG2D receptor or KIR respectively (25, 26). Elimination of these tumor cells may go undetected until a macroscopic skin tumor, devoid of NK-activating ligands or expressing NK-inhibitory ligands like HLA-G (26), comes to the attention of the patient or doctor. It is likely that, at that time, HLA-A, -B and -C-restricted alphabeta T cells remain the main players in the immune recognition of HLA-restricted melanoma antigens. However, in association with the down-regulation or disappearance of class I HLA, a re-activation of the NKT, NKG2D+ infiltrating lymphocytes may also occur in metastatic lesions while expression of MIC is not modified (27).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Flow chart of the possible kinetics of interactions between melanoma and alphabeta T cells of tumor-bearing patients. Early T cell response may or not be activated (left, central and right upper panel). If activated (left and central panel), T cells can preferentially recognize strongly immunogenic unique antigens. T cell recognition may result in either complete or partial reduction of the most immunogenic and metastasis competent tumor cells. Patients whose immunogenic/metastasis competent cells are eliminated will then be cured by surgery (left panel), whereas partial elimination of such neoplastic cells will allow recurrences to occur in at least a fraction of the patients. Patients in whom no immune recognition in the primary lesion takes place (right panel) will recur with a high frequency. Vaccination of metastatic patients with antigens which have been selected against during tumor growth will be ineffective due to the lack or low expression of common differentiation antigens and the useless high frequency of CTLps directed to unique antigens, these unique antigens not being included in the vaccine. However, patients whose T cells failed to recognize unique and/or differentiation antigens during tumor growth could be prone to respond to vaccines containing differentiation antigens should the vaccine formulation result in priming of naive T cells (e.g. using DC) that can find their target (differentiation antigens) or the antigenically unselected tumor cells.

However, even alphabeta T cells may fail to recognize primary tumors despite their antigenic potential for a variety of reasons, including (i) the possible detrimental effect on antigen-presenting cell (APC) function and on T-cells accompanying the process of neoplastic transformation of melanocytes caused by UV irradiation (28, 29), and (ii) the production of a variety of cytokines (30) and the expression or release of FasL (31) by tumor cells that could locally suppress an otherwise effective immune response (tumor counterattack), though the latter phenomenon remains controversial (32). In such cases, no effective local or systemic immunization will take place and, therefore, no tumor antigen selection will ensue.

As a consequence, the circulating tumor cells of these two clinically similar groups of patients whose primary melanoma has been surgically removed (i.e. those who mounted an immune response against the primary neoplasm and those who did not) should be antigenically different, the melanomas of the first group having lost one or more epitope/HLA complexes in a significant fraction of tumor cells whereas the melanomas of the second group maintain their original, unmodified antigenic profile. These two groups of patients should also show marked differences in terms of specific cytotoxic T lymphocyte precursors (CTLp) and effectors to different melanoma antigens, with patients who mounted an immune response during early tumor growth having a high frequency of these memory CTLs in their blood and/or tissues, whereas individuals in whom no immunization occurred and therefore bearing unselected neoplastic cells having negligible numbers of anti-melanoma CTLs (Figure 1).

Tumor antigens recognized in early vs. metastatic neoplastic lesions

Which cells are eliminated in such an early phase and which is the molecular identity of the targeted antigens on primary tumors is unknown. We favor the idea that alphabetaT cells infiltrating primary melanomas probably predominantly recognize antigens forming an entirely new epitope in neoplastic, as compared to normal, cells (for a list of such antigens, refer to 33). In fact, a large number of somatic mutations accumulate in cancer cells in response to both environmental agents (such as the UV component of sunlight, ionizing radiation, chemicals) and products of normal cellular metabolism. Mouse models have clearly demonstrated that UV rays, the main culprit of human melanoma, can induce tumors bearing several unique, strong antigens (34). Some of these somatic mutations will result in proteins that provide novel immunogenic peptides (epitopes) recognized in the context of at least some HLA molecules. However, depending on the gene affected, the immune system may face two different situations, owing to the fact that some of these gene products are irrelevant to the tumorigenic process whereas others can have a crucial role in the development and progression of the tumor. In both cases the new epitope may elicit a strong immune T-cell response that may result in antigen-loss cancer cell variants. However, while antigen-loss variants are likely to be generated in tumor cells bearing the mutated, but growth-unrelated epitope, the immune response will have to cope with the inherent advantage offered by the altered protein to the malignant phenotype when a growth-indispensable gene is involved. Thus one may predict that the latter, but not the first, type of unique antigens should be found in metastatic lesions, a hypothesis which appears to be corroborated by the admittedly few available data on the molecular characterization of unique antigens in melanoma. In fact, while the only unique antigen described in primary melanoma is the result of a mutation in myosin (35), certainly not a growth-related protein, unique antigens of metastatic tumors derive from mutated carcinogenesis- and growth-related proteins or essential housekeeping genes like N-RAS (36), p16INK4a (37), beta-catenin (38), ribosomal-like proteins (39), caspase-8 (40) or MUM-2, a protein with an essential function in eukaryotic cells (41). Conversely, tumor antigens corresponding to differentially-expressed normal protein/peptides (differentiation antigens) or similar antigens expressed only in particular normal tissues, i.e. testis, but often expressed in primary tumors (e.g. MAGE, NY-ESO-1) should be less susceptible to immune selection due to their weak or null "spontaneous" immunogenicity that may result from several factors (42). A possible exception is Melan-A/MART-1, which is considered the immunodominant antigen both in vitro and in vivo as compared to other melanoma differentiation antigens (43, 44). In fact, it was recently found that primary melanoma regression is associated with an immune response to Melan-A/MART-1 which causes a selection for antigen-negative cell variants (45). This possibility was confirmed by an analysis of healthy controls and melanoma patients in different clinical conditions by HLA-A2/epitope tetramer staining. Such a study has revealed a low but detectable frequency of anti-Melan-A/MART-1 but no or appreciably fewer anti-gp100 or -tyrosinase T cells in stage I patients (primary tumor); however, the frequency of T cells recognizing all three antigens studied increases with increasing tumor burden in the advanced disease (46). Moreover, T lymphocytes of HLA-A2 metastatic (stage III) melanoma patients treated with surgery alone only seldom recognized unique antigens on autologous (possibly immunoselected) metastatic melanoma, whereas T cells recognizing differentiation antigens were found in most of these patients (47). The possible anti-tumor activity of T cells directed to unique antigens is suggested by the detection of unique antigens endowed with pro-tumorigenic properties in metastatic melanoma and non-melanoma patients enjoying a favorable prognosis (39, 48, 49). In such patients, tetramer staining with soluble HLA/peptide complexes revealed a high frequency of CTLs, often clonally expanded, directed against these unique mutated peptides. These effectors persisted for a long time (48, 49) and were often accompanied by a loss of previously recognized tumor antigens (48). This suggests that, in these patients, a systemic immunization against unique tumor-specific antigens may occur during primary tumor growth and when antigen-bearing cells are not eliminated, such an immunization can effectively help to control the progression of the disease. Evidently, these mutations affect proteins which cannot be lost by tumor cells, as has recently been shown for ribosomal proteins serving as unique antigens in mice (50).

Shaping of the tumor cell antigenic phenotype during progression

In patients who mounted an immune response, the early difference in tumor antigen expression with patients who failed to do so could be quantitatively and qualitatively accentuated during the period of clinically silent metastatic growth (e.g. invasion of draining lymph nodes). Moreover, inflammatory-like reactions at the site of tumor growth or other favorable factors may help the host's immune system to break tolerance and to become primed against melanoma antigens formed by normal proteins (e.g. Melan-A/MART-1, MAGE) as well, thus giving rise to a second round of immunoselection driven by such antigens (refer to Figure 1).

Spontaneous immunoselection has been documented by several reports where different metastatic nodules of the same melanoma patient could be tested at different time points, showing a progressive loss of tumor antigen/HLA complex epitopes derived from normal proteins (51, 52, 53).

Thus, in advanced melanoma patients in whom immunoselection has occurred, the T cell repertoire will have a heterogeneous composition. In fact, it would include CTLs recognizing tumor-restricted (unique or shared) early epitopes maintained, in a minority of patients, on primary and metastatic cells owing to the growth advantage conferred by such epitopes to melanoma cells. An additional subset of CTLs will encompass those recognizing normal, shared antigens (like tyrosinase, MAGE, etc.) encountered in the subsequent metastatic phase of the disease, in addition to the anti-Melan-A/MART-1 effectors generated during primary tumor growth (45, 54, 55). In addition, it is also likely that priming against the latter melanoma antigens may occur more frequently in advanced disease owing to (i) a larger antigen burden, as suggested by the work of Dunbar (56) and shown in a large series of melanoma patients studied in our institute (46), and/or (ii) a higher level of gene expression possibly associated with increasing de-methylation occurring during tumor growth (57).

Effect of vaccination

Vaccinations have been and are being carried out in advanced metastatic patients that, for the reasons outlined above, may belong to two distinct immunological and clinical subsets (refer to Figure 1).

The first group includes patients whose metastases consist of cells which have gone through a CTL-mediated immune selection during primary and metastatic tumor growth. It should be pointed out that, to date, all vaccination protocols have involved immunization against shared tumor antigens, irrespective of the vaccination mode (peptide, protein or recombinant vaccine). The only exceptions may be represented by autologous tumor cell vaccines (58) or autologous heat shock protein gp96 vaccines (59) which may contain unique antigens, although not demonstrated in these clinical trials. Thus, at present, the role (if any) of unique antigens in human cancer vaccination is entirely unknown. As for shared antigens, a clinical response will fail in these patients if the vaccine includes peptide epitopes previously seen by their immune system but present only in a fraction of metastatic cells. This is likely to have occurred in many trials. In fact, only some clinical vaccination protocols required, among the eligibility criteria, an assessment of the expression in metastatic biopsies of the antigen used in the vaccine. Moreover, this assessment often consisted of only a non-quantitative PCR allowing large, but still partial, loss of antigen(s) by melanoma cells to go undetected. In other cancer patients the metastatic lesions affect visceral organs from which even fine-needle biopsies cannot be obtained. In such cases a functional dissociation may occur between the lack of local immune response at metastatic tumor sites and the systemic anti-tumor reaction (60). In fact, in these same patients, a strong anti-vaccine T cell immunity could be expected to develop if the vaccine includes tumor-specific antigens against which a high frequency of CTLps have been expanded during previous tumor growth.

The second group of patients, whose immune system has ignored tumor antigens corresponding to normal proteins throughout tumor growth, therefore has few or no CTLps against them. These subjects, who may include up to 50% of metastatic patients (61, 62), if appropriately immunized with multiepitope vaccines, may be those in whom the CTL response has the highest chance of recognizing epitopes expressed by the previously unselected tumor cells and therefore cause significant tumor destruction, ultimately leading to a clinically-relevant shrinkage of the tumor mass. In these patients the relatively low frequency of CTLps (due to the absence of or limited boosting during tumor growth) will reduce the possibility of detecting anti-melanoma specific CTLs in the blood, such effectors being concentrated in tumor lesions to function as killer cells. This group of metastatic patients will most likely need to be immunized using potent antigen-presenting cells (e.g. DCs) and T helper epitopes because priming is necessary to break/activate their tolerant/ignorant immune system. The number of vaccinations may also be relevant in determining immune and clinical responses as recently shown in an animal model (63). As suggested by the long time necessary for the clinical response to become evident, this may have occurred with patients who showed a durable clinical response in the vaccination trial with the MAGE-3.A1 peptide (4).

Evaluation of the expression of the tumor antigen(s) included in the vaccine, as well as of the frequency of CTLps directed against these in peripheral blood and, when possible, at the tumor site, will allow this hypothesis to be tested in future clinical trials.

A recent publication reported on a successful vaccination of follicular B lymphoma patients (64). In this instance, important drawbacks which occur in patients bearing metastatic solid tumors, such as the heterogeneity of tumor antigens, their selection by the immune system and the large tumor burden were overcome by the tumor system used. In fact, these lymphomas express an operationally homogeneous tumor antigen (the Ig idiotype) on all neoplastic cells, thus representing an ideal target for the immune reactivity elicited by vaccination. Moreover, chemotherapy renders these patients clinically tumor-free, though molecularly detectable lymphoma cells can still be found in the majority of patients whose tumor burden is therefore very limited and unable to activate important tumor escape mechanism. These factors thus facilitate the destructive action of the tumor-specific immune cells induced by the vaccine. It should also be noted that until vaccination is initiated, lymphoma patients do not appear to have developed a spontaneous anti-tumor immunity, thus resembling the subgroup of immunologically tolerant melanoma patients discussed above.

Acknowledgments

The authors' work was supported by the Italian Association for Cancer Research (Milano), by the Italian Ministry of Health (Finalized Projects) and by the European Community (Grant QLK3-1999-00064).

  • Copyright © 2002 by Giorgio Parmiani

References

  1. 1.↵
    1. Jaeger E,
    2. Bernhard H,
    3. Romero P,
    4. Ringhoffer M,
    5. Arand M,
    6. Karbach J,
    7. Ilsemann C,
    8. Hagedorn M,
    9. Knuth A
    . Generation of cytotoxic T-cell response with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996;66:162–9.pmid:8603805
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Nestle FO,
    2. Alijagic S,
    3. Gilliet M,
    4. Sun Y,
    5. Grabbe S,
    6. Dummer R,
    7. Burg G,
    8. Schadendorf D
    . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328–32.pmid:9500607
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Rosenberg SA,
    2. Yang JC,
    3. Schwartzentruber DJ,
    4. Hwu P,
    5. Marincola FM,
    6. Topalian SL,
    7. Restifo NP,
    8. Dudley ME,
    9. Schwarz SL,
    10. Spiess PJ,
    11. Wunderlich JR,
    12. Parkhurst MR,
    13. Kawakami Y,
    14. Seipp CA,
    15. Einhorn JH,
    16. White DE
    . Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321–7.pmid:9500606
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Marchand M,
    2. van Baren N,
    3. Weynants P,
    4. Brichard V,
    5. Dreno B,
    6. Tessier MH,
    7. Rankin E,
    8. Parmiani G,
    9. Arienti F,
    10. Humblet Y,
    11. Bourlond A,
    12. Vanwijck R,
    13. Lienard D,
    14. Beauduin M,
    15. Dietrich PY,
    16. Russo V,
    17. Kerger J,
    18. Masucci G,
    19. Jager E,
    20. De Greve J,
    21. Atzpodien J,
    22. Brasseur F,
    23. Coulie PG,
    24. van der Bruggen P,
    25. Boon T
    . Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219–30.pmid:9935203
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Thurner B,
    2. Haendle I,
    3. Roder C,
    4. Dieckmann D,
    5. Keikavoussi P,
    6. Jonuleit H,
    7. Bender A,
    8. Maczek C,
    9. Schreiner D,
    10. von den Driesch P,
    11. Brocker EB,
    12. Steinman RM,
    13. Enk A,
    14. Kampgen E,
    15. Schuler G
    . Vaccination with Mage-3A1 peptide-pulsed mature monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669–78.pmid:10587357
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Jager E,
    2. Gnjatic S,
    3. Nagata Y,
    4. Stockert E,
    5. Jager D,
    6. Karbach J,
    7. Neumann J,
    8. Rieckenberg J,
    9. Chen YT,
    10. Ritter G,
    11. Hoffman E,
    12. Arand M,
    13. Old LJ,
    14. Knuth A
    . Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000;97:12198–203.pmid:11027314
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Lee P,
    2. Wang F,
    3. Kuniyoshi J,
    4. Rubio V,
    5. Stuges T,
    6. Groshen S,
    7. Gee C,
    8. Lau R,
    9. Jeffery G,
    10. Margolin K,
    11. Marty V,
    12. Weber J
    . Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001;19:3836–47.pmid:11559721
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Gjertsen MK,
    2. Buanes T,
    3. Rosseland AR,
    4. Bakka A,
    5. Gladhaug I,
    6. Soreide O,
    7. Eriksen JA,
    8. Moller M,
    9. Baksaas I,
    10. Lothe RA,
    11. Saeterdal I,
    12. Gaudernack G
    . Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441–50.pmid:11291084
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Murphy GP,
    2. Tjoa BA,
    3. Simmons SJ,
    4. Jarisch J,
    5. Bowes VA,
    6. Ragde H,
    7. Rogers M,
    8. Elgamal A,
    9. Kenny GM,
    10. Cobb OE,
    11. Ireton RC,
    12. Troychak MJ,
    13. Salgaller ML,
    14. Boynton AL
    . Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999;38:73–8.pmid:9973112
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Cormier JN,
    2. Salgaller ML,
    3. Prevette T,
    4. Barracchini KC,
    5. Rivoltini L,
    6. Restifo NP,
    7. Rosenberg SA,
    8. Marincola FM
    . Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan-A. Cancer J Sci Am 1997;3:37–44.pmid:9072306
    OpenUrlPubMed
  11. 11.↵
    1. Lee KH,
    2. Wang E,
    3. Nielsen MB,
    4. Wunderlich J,
    5. Migueles S,
    6. Connors M,
    7. Steinberg SM,
    8. Rosenberg SA,
    9. Marincola FM
    . Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999;163:6292–300.pmid:10570323
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Schuler-Thurner B,
    2. Dieckmann D,
    3. Keikavoussi P,
    4. Bender A,
    5. Maczek C,
    6. Jonuleit H,
    7. Roder C,
    8. Haendle I,
    9. Leisgang W,
    10. Dunbar R,
    11. Cerundolo V,
    12. von Den Driesch P,
    13. Knop J,
    14. Brocker EB,
    15. Enk A,
    16. Kampgen E,
    17. Schuler G
    . Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000;165:3492–6.pmid:10975870
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Wang F,
    2. Bade E,
    3. Kuniyoshi C,
    4. Spears L,
    5. Jeffery G,
    6. Marty V,
    7. Groshen S,
    8. Weber J
    . Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756–65.pmid:10537339
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Zhu MZ,
    2. Marshall J,
    3. Cole D,
    4. Schlom J,
    5. Tsang KY
    . Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 2000;6:24–33.pmid:10656428
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Lodge PA,
    2. Jones LA,
    3. Bader RA,
    4. Murphy GP,
    5. Salgaller ML
    . Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000;60:829–33.pmid:10706088
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Clark WH Jr,
    2. Elder DE,
    3. Guerry D 4th,
    4. Braitman LE,
    5. Trock BJ,
    6. Schultz D,
    7. Synnestvedt M,
    8. Halpern AC
    . Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893–904.pmid:2593166
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Tefany FJ,
    2. Barnetson RS,
    3. Halliday GM,
    4. McCarthy SW,
    5. McCarthy WH
    . Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991;97:197–202.pmid:1712819
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Mackensen A,
    2. Carcelain G,
    3. Viel S,
    4. Raynal MC,
    5. Michalaki H,
    6. Triebel F,
    7. Bosq J,
    8. Hercend T
    . Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest 1994;93:1397–402.pmid:8163644
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Pisarra P,
    2. Mortarini R,
    3. Salvi S,
    4. Anichini A,
    5. Parmiani G,
    6. Sensi M
    . High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition. Cancer Immunol Immunother 1999;48:39–46.pmid:10235487
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Wagner SN,
    2. Schultewolter T,
    3. Wagner C,
    4. Briedigkeit L,
    5. Becker JC,
    6. Kwasnicka HM,
    7. Goos M
    . Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest 1998;78:541–50.pmid:9605179
    OpenUrlPubMed
  21. 21.↵
    1. Clemente CG,
    2. Mihm MC Jr,
    3. Bufalino R,
    4. Zurrida S,
    5. Collini P,
    6. Cascinelli N
    . Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303–10.pmid:8608507
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Ferrone S,
    2. Marincola FM
    . Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487–94.pmid:7576053
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Shankaran V,
    2. Ikeda H,
    3. Bruce AT,
    4. White JM,
    5. Swanson PE,
    6. Old LJ,
    7. Schreiber RD
    . IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107–11.pmid:11323675
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Girardi M,
    2. Oppenheim DE,
    3. Steele CR,
    4. Lewis JM,
    5. Glusac E,
    6. Filler R,
    7. Hobby P,
    8. Sutton B,
    9. Tigelaar RE,
    10. Hayday AC
    . Regulation of cutaneous malignancy by gammadelta T cells. Science 2001;294:605–9.pmid:11567106
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Bauer S,
    2. Groh V,
    3. Wu J,
    4. Steinle A,
    5. Phillips JH,
    6. Lanier LL,
    7. Spies T
    . Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727–9.pmid:10426993
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Cabestre FA,
    2. Moreau P,
    3. Riteau B,
    4. Ibrahim EC,
    5. Le Danff C,
    6. Dausset J,
    7. Rouas-Freiss N,
    8. Carosella ED,
    9. Paul P
    . HLA-G expression in human melanoma cells: protection from NK cytolysis. J Reprod Immunol 1999;43:183–93.pmid:10479054
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Vetter CS,
    2. Groh V,
    3. thor Straten P,
    4. Spies T,
    5. Brocker EB,
    6. Becker JC
    . Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol 2002;118:600–5.pmid:11918705
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Kripke ML
    . Ultraviolet radiation and immunology: something new under the sun-presidential address. Cancer Res 1994;54:6102–5.pmid:7954455
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Shreedhar VK,
    2. Pride MW,
    3. Sun Y,
    4. Kripke ML,
    5. Strickland FM
    . Origin and characteristics of ultraviolet-B radiation-induced suppressor T lymphocytes. J Immunol 1998;161:1327–35.pmid:9686595
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Conrad CT,
    2. Ernst NR,
    3. Dummer W,
    4. Brocker EB,
    5. Becker JC
    . Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J Exp Clin Cancer Res 1999;18:225–32.pmid:10464712
    OpenUrlPubMed
  31. 31.↵
    1. Andreola G,
    2. Rivoltini L,
    3. Castelli C,
    4. Huber V,
    5. Perego P,
    6. Deho P,
    7. Squarcina P,
    8. Accornero P,
    9. Lozupone F,
    10. Lugini L,
    11. Stringaro A,
    12. Molinari A,
    13. Arancia G,
    14. Gentile M,
    15. Parmiani G,
    16. Fais S
    . Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303–16.pmid:12021310
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Restifo NP
    . Countering the 'counterattack' hypothesis. Nat Med 2001;7:259.pmid:11231598
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Renkvist N,
    2. Castelli C,
    3. Robbins PF,
    4. Parmiani G
    . A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3–15.pmid:11315507
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Urban JL,
    2. Schreiber H
    . Tumor antigens. Annu Rev Immunol 1992;10:617–44.pmid:1590998
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Zorn E,
    2. Hercend T
    . A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 1999;29:592–601.pmid:10064075
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. van 't Veer LJ,
    2. Burgering BM,
    3. Versteeg R,
    4. Boot AJ,
    5. Ruiter DJ,
    6. Osanto S,
    7. Schrier PI,
    8. Bos JL
    . N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989;9:3114–6.pmid:2674680
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Wolfel T,
    2. Hauer M,
    3. Schneider J,
    4. Serrano M,
    5. Wolfel C,
    6. Klehmann-Hieb E,
    7. De Plaen E,
    8. Hankeln T,
    9. Meyer zum Buschenfelde KH,
    10. Beach D
    . A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281–4.pmid:7652577
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Robbins PF,
    2. El-Gamil M,
    3. Li YF,
    4. Kawakami Y,
    5. Loftus D,
    6. Appella E,
    7. Rosenberg SA
    . A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185–92.pmid:8642260
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Karanikas V,
    2. Colau D,
    3. Baurain JF,
    4. Chiari R,
    5. Thonnard J,
    6. Gutierrez-Roelens I,
    7. Goffinet C,
    8. Van Schaftingen EV,
    9. Weynants P,
    10. Boon T,
    11. Coulie PG
    . High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001;61:3718–24.pmid:11325844
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Mandruzzato S,
    2. Stroobant V,
    3. Demotte N,
    4. van der Bruggen P
    . A human CTL recognizes a caspase-8-derived peptide on autologous HLA-B*3503 molecules and two unrelated peptides on allogeneic HLA-B*3501 molecules. J Immunol 2000;164:4130–4.pmid:10754307
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Chiari R,
    2. Foury F,
    3. De Plaen E,
    4. Baurain JF,
    5. Thonnard J,
    6. Coulie PG
    . Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res 1999;59:5785–92.pmid:10582700
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Parmiani G
    . Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today 1993;14:536–8.pmid:8274196
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Spagnoli GC,
    2. Schaefer C,
    3. Willimann TE,
    4. Kocher T,
    5. Amoroso A,
    6. Juretic A,
    7. Zuber M,
    8. Luscher U,
    9. Harder F,
    10. Heberer M
    . Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int J Cancer 1995;64:309–15.pmid:7591302
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Mateo L,
    2. Gardner J,
    3. Chen Q,
    4. Schmidt C,
    5. Down M,
    6. Elliott SL,
    7. Pye SJ,
    8. Firat H,
    9. Lemonnier FA,
    10. Cebon J,
    11. Suhrbier A
    . An HLA-A2 polyepitope vaccine for melanoma immunotherapy. J Immunol 1999;163:4058–63.pmid:10491010
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Saleh FH,
    2. Crotty KA,
    3. Hersey P,
    4. Menzies SW
    . Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int J Cancer 2001;94:551–7.pmid:11745443
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Mortarini R,
    2. Molla A,
    3. Maurichi A,
    4. Bartoli C,
    5. Bono A,
    6. Lombardo C,
    7. Piris A,
    8. Cascinelli N,
    9. Parmiani G,
    10. Anichini A
    . Melanoma progression and epitope immunogenicity shape CD8+ T cell-mediated immunity. Manuscript submitted for publication. 
  47. 47.↵
    1. Anichini A,
    2. Mortarini R,
    3. Maccalli C,
    4. Squarcina P,
    5. Fleischhauer K,
    6. Mascheroni L,
    7. Parmiani G
    . Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 1996;156:208–17.pmid:8598464
    OpenUrlAbstract
  48. 48.↵
    1. Coulie PG,
    2. Ikeda H,
    3. Baurain JF,
    4. Chiari R
    . Antitumor immunity at work in a melanoma patient. Adv Cancer Res 1999;76:213–42.pmid:10218103
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Baurain JF,
    2. Colau D,
    3. Van Baren N,
    4. Landry C,
    5. Martelange V,
    6. Vikkula M,
    7. Boon T,
    8. Coulie PG
    . High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J Immunol 2000;164:6057–66.pmid:10820291
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Beck-Engeser GB,
    2. Monach PA,
    3. Mumberg D,
    4. Yang F,
    5. Wanderling S,
    6. Schreiber K,
    7. Espinosa R 3rd,
    8. Le Beau MM,
    9. Meredith SC,
    10. Schreiber H
    . Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens. J Exp Med 2001;194:285–300.pmid:11489948
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Lehmann F,
    2. Marchand M,
    3. Hainaut P,
    4. Pouillart P,
    5. Sastre X,
    6. Ikeda H,
    7. Boon T,
    8. Coulie PG
    . Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340–7.pmid:7875194
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Maeurer MJ,
    2. Gollin SM,
    3. Martin D,
    4. Swaney W,
    5. Bryant J,
    6. Castelli C,
    7. Robbins P,
    8. Parmiani G,
    9. Storkus WJ,
    10. Lotze MT
    . Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996;98:1633–41.pmid:8833913
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Ikeda H,
    2. Lethe B,
    3. Lehmann F,
    4. van Baren N,
    5. Baurain JF,
    6. de Smet C,
    7. Chambost H,
    8. Vitale M,
    9. Moretta A,
    10. Boon T,
    11. Coulie PG
    . Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199–208.pmid:9047241
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Carcelain G,
    2. Rouas-Freiss N,
    3. Zorn E,
    4. Chung-Scott V,
    5. Viel S,
    6. Faure F,
    7. Bosq J,
    8. Hercend T
    . In situ T-cell responses in a primary regressive melanoma and subsequent metastases: a comparative analysis. Int J Cancer 1997;72:241–7.pmid:9219827
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Palermo B,
    2. Campanelli R,
    3. Mantovani S,
    4. Lantelme E,
    5. Manganoni AM,
    6. Carella G,
    7. Da Prada G,
    8. della Cuna GR,
    9. Romagne F,
    10. Gauthier L,
    11. Necker A,
    12. Giachino C
    . Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients. Eur J Immunol 2001;31:412–20.pmid:11180105
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Dunbar PR,
    2. Smith CL,
    3. Chao D,
    4. Salio M,
    5. Shepherd D,
    6. Mirza F,
    7. Lipp M,
    8. Lanzavecchia A,
    9. Sallusto F,
    10. Evans A,
    11. Russell-Jones R,
    12. Harris AL,
    13. Cerundolo V
    . A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 2000;165:6644–52.pmid:11086110
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Coral S,
    2. Sigalotti L,
    3. Gasparollo A,
    4. Cattarossi I,
    5. Visintin A,
    6. Cattelan A,
    7. Altomonte M,
    8. Maio M
    . Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR) J Immunother 1999;22:16–24.pmid:9924695
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Berd D,
    2. Sato T,
    3. Cohn H,
    4. Maguire HC Jr,
    5. Mastrangelo MJ
    . Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer 2001;94:531–9.pmid:11745440
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Belli F,
    2. Testori A,
    3. Rivoltini L,
    4. Maio M,
    5. Andreola G,
    6. Sertoli MR,
    7. Gallino P,
    8. Piris A,
    9. Cattelan A,
    10. Lazzari I,
    11. Carrabba M,
    12. Scita G,
    13. Santantonio C,
    14. Pilla L,
    15. Tragni G,
    16. Lombardo C,
    17. Arienti F,
    18. Marchianò A,
    19. Bertolini F,
    20. Cova A,
    21. Lamaj E,
    22. Ascani L,
    23. Camerini R,
    24. Corsi M,
    25. Cascinelli N,
    26. Srivastava PK,
    27. Lewis JJ,
    28. Parmiani G
    . Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein peptide-complex-96 (Oncophage®): clinical and immunological findings. J Clin Oncol. In press 2002. 
  60. 60.↵
    1. Lee KH,
    2. Panelli MC,
    3. Kim CJ,
    4. Riker AI,
    5. Bettinotti MP,
    6. Roden MM,
    7. Fetsch P,
    8. Abati A,
    9. Rosenberg SA,
    10. Marincola FM
    . Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 1998;161:4183–94.pmid:9780192
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Anichini A,
    2. Molla A,
    3. Mortarini R,
    4. Tragni G,
    5. Bersani I,
    6. Di Nicola M,
    7. Gianni AM,
    8. Pilotti S,
    9. Dunbar R,
    10. Cerundolo V,
    11. Parmiani G
    . An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999;190:651–67.pmid:10477550
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Romero P,
    2. Dunbar PR,
    3. Valmori D,
    4. Pittet M,
    5. Ogg GS,
    6. Rimoldi D,
    7. Chen JL,
    8. Lienard D,
    9. Cerottini JC,
    10. Cerundolo V
    . Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641–50.pmid:9802976
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Perez-Diez A,
    2. Spiess PJ,
    3. Restifo NP,
    4. Matzinger P,
    5. Marincola FM
    . Intensity of the vaccine-elicited immune response determines tumor clearance. J Immunol 2002;168:338–47.pmid:11751979
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Bendandi M,
    2. Gocke CD,
    3. Kobrin CB,
    4. Benko FA,
    5. Sternas LA,
    6. Pennington R,
    7. Watson TM,
    8. Reynolds CW,
    9. Gause BL,
    10. Duffey PL,
    11. Jaffe ES,
    12. Creekmore SP,
    13. Longo DL,
    14. Kwak LW
    . Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171–7.pmid:10502821
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Immunity Archive: 2 (1)
January 2002
Volume 2, Issue 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
T-cell response to unique and shared antigens and vaccination of cancer patients
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
T-cell response to unique and shared antigens and vaccination of cancer patients
Giorgio Parmiani, Marialuisa Sensi, Chiara Castelli, Licia Rivoltini and Andrea Anichini
Cancer Immun January 1 2002 (2) (1) 6;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
T-cell response to unique and shared antigens and vaccination of cancer patients
Giorgio Parmiani, Marialuisa Sensi, Chiara Castelli, Licia Rivoltini and Andrea Anichini
Cancer Immun January 1 2002 (2) (1) 6;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Tumor-host relationship during primary tumor growth
    • Tumor antigens recognized in early vs. metastatic neoplastic lesions
    • Shaping of the tumor cell antigenic phenotype during progression
    • Effect of vaccination
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • NY-ESO-1–specific immunological pressure and escape in a patient with metastatic melanoma
  • Hsp72 mediates stronger antigen-dependent non-classical MHC class Ib anti-tumor responses than hsc73 in Xenopus laevis
  • Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement